DexCom, Inc. (DXCM)

66.96 -1.98 (-2.87%) USD  |  NASDAQ  |  Dec 12, 16:00
66.85 -0.11 (-0.16%) After-Hours: 20:00
More

DexCom Research and Development Expense (Quarterly): 157.50M for Sept. 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for DXCM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Abbott Laboratories 748.00M
BioLife Solutions, Inc. 2.709M
Eli Lilly & Co. 3.466B
Sotera Health Co. --
Regeneron Pharmaceuticals, Inc. 1.338B